Results 31 to 40 of about 5,019 (231)

T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions

Frontiers in Oncology, 2023
Several key advances in the treatment of B-cell non-Hodgkin lymphoma (B-NHL) over the past two decades have strategically exploited B-cell lineage markers suitable for targeting by immunotherapies. First, the addition of the anti-CD20 monoclonal antibody
David A. Russler-Germain, David A. Russler-Germain, Armin Ghobadi, Armin Ghobadi   +3 more
doaj   +1 more source

BiTE-ing into Prostate Cancer with Bispecific T-cell Engagers

Clinical Cancer Research, 2021
Abstract Targeting prostate-specific membrane antigen (PSMA) has important therapeutic ramifications, more recently including immune oncology. Data were recently presented on the preclinical efficacy of a half-life extended bispecific T-cell engager, AMG 160, which binds PSMA and CD3 to induce T-cell–driven cytolytic activity against ...
Nikhil V. Kamat, Evan Y. Yu, John K. Lee
openaire   +3 more sources

Administering Blinatumomab via Continuous Intravenous Infusion in Pediatric Patients—A Single‐Institution Retrospective Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab, a CD19xCD3 bispecific T‐cell engager, has become standard therapy for children with de novo B‐cell acute lymphoblastic leukemia (B‐ALL). This retrospective review describes the experience of blinatumomab administration in pediatric patients.
Julia M. Hurley, Ryleigh Krueger, Kellie Joyce, James Stanley, Mary Waskerwitz‐Freyer, Marielle Klunder, David J. Hoogstra   +6 more
wiley   +1 more source

Occurrence of Extramedullary Relapses in Pediatric Acute Lymphoblastic Leukemia After Treatment With Blinatumomab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT We report a retrospective single‐center analysis of pediatric patients with relapsed or refractory B‐cell precursor acute lymphoblastic leukemia focusing on relapses outside of the typical locations, bone marrow, central nervous system, or testes.
Johanna Kunz, Martin Ebinger, Michaela Döring, Markus Mezger, Ursula Holzer, Rupert Handgretinger, Peter Lang, Manon Queudeville   +7 more
wiley   +1 more source

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion

mAbs
B cell maturation antigen (BCMA) is a validated target for plasma cell depletion; however, T cell–redirecting approaches must balance potent cytotoxicity with controlled T cell activation.
Jamie Thomas, Gang Xu, Hannah Lock, Qin Song, Yumei Yin, Wanying Luo, Kyu Hong, Liguang Lou, Changyu Wang, Leslie Chinn, Neelufar Mozaffarian, Jaideep Dudani, Paul Bessette, Charlie Zhou, Ruth Lan, Bo Chen, Nishant Mehta   +16 more
doaj   +1 more source

Nanomaterial Strategies for Pulmonary Delivery of Immunotherapeutics in Lung Cancer Treatment

Advanced Healthcare Materials, EarlyView.
Inhalable immunotherapeutic nanomedicines enable organ‐selective immune modulation by overcoming pulmonary delivery barriers and concentrating therapy within lung tumors. This Review defines how nanomaterial properties govern airway deposition, retention, cellular partitioning, and immune activation across vaccines, checkpoint blockade, STING agonists,
Han Zhang, Wei Tang
wiley   +1 more source

TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy

Signal Transduction and Targeted Therapy
T cell engager (TCE) immunotherapies have revolutionized the landscape of cancer treatment; however, their efficacy remains limited by the inaccessibility of intracellular tumor antigens.
Ziqiang Ding, Shuyang Sun, Xiaomei Yang, Xianing Huang, Xiaoqiong Hou, Shenxia Xie, Aiqun Liu, Xiaoling Lu   +7 more
doaj   +1 more source

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy

Biomedicines, 2020
Oncolytic viruses (OVs) are potent anti-cancer biologics with a bright future, having substantial evidence of efficacy in patients with cancer. Bi- and tri-specific antibodies targeting tumor antigens and capable of activating T cell receptor signaling ...
Zong Sheng Guo, Michael T. Lotze, Zhi Zhu, Walter J. Storkus, Xiao-Tong Song   +4 more
doaj   +1 more source

Visualizing Spatial and Stoichiometric Barriers to Bispecific T-cell Engager EfficacyVisualizing Barriers to Bispecific T-cell Engager Efficacy [PDF]

, 2022
Bispecific T-cell engager (BiTE) molecules are biologic T cell-directing immunotherapies. Blinatumomab is approved for treatment of B-cell malignancies, but BiTE molecule development in solid tumors has been more challenging. Here, we employed intravital imaging to characterize exposure and pharmacodynamic response of an anti-muCD3/anti-huEGFRvIII ...
You, Ran, Artichoker, Jordan, Ray, Arja, Velozo, Hugo Gonzalez, Rock, Dan A, Conner, Kip P, Krummel, Matthew F   +6 more
openaire   +1 more source